Xenon Pharmaceuticals Inc. (XENE)

Xenon Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	58.9	148.64	57.24	175.69	45.01	24.76
Short-Term Investments	640.71	489.44	534.85	376.09	131.99	116.6
Cash & Cash Equivalents	699.6	638.08	592.09	551.77	177	141.36
Cash Growth	32.74%	7.77%	7.31%	211.74%	25.21%	18.48%
Receivables	0.83	0.87	0.99	2.77	1.82	0.81
Other Current Assets	6.77	6.01	7.23	4.48	2.96	2.7
Total Current Assets	707.2	644.96	600.3	559.02	181.78	144.87
Property, Plant & Equipment	18.28	18.85	16.91	12.52	6.88	2.59
Long-Term Investments	185.84	292.79	128.68	0	0	0
Other Long-Term Assets	7.71	8.2	8.26	0.47	0.52	0.24
Total Long-Term Assets	211.82	319.84	153.85	12.99	7.4	2.83
Total Assets	919.02	964.8	754.15	572.01	189.19	147.7
Accounts Payable	20.9	25.97	22.21	13.72	10.87	8.82
Deferred Revenue	0	0	0	0	3.64	30.45
Current Debt	1.32	1.3	0.49	0.61	0.27	4.82
Other Current Liabilities	0	0	0	0	0	-0.71
Total Current Liabilities	22.22	27.27	22.7	14.32	14.78	43.38
Long-Term Debt	9.1	9.6	9.95	7.65	3.05	11.63
Other Long-Term Liabilities	0	0	0	0	0	0.71
Total Long-Term Liabilities	9.1	9.6	9.95	7.65	3.05	12.34
Total Liabilities	31.33	36.88	32.65	21.97	17.83	55.72
Total Debt	10.43	10.9	10.44	8.26	3.32	16.45
Debt Growth	-10.34%	4.48%	26.38%	149.08%	-79.85%	9.56%
Retained Earnings	-713.07	-665.14	-482.75	-357.37	-278.49	-249.66
Comprehensive Income	-1.77	-0.08	-3	-0.99	-0.99	-0.99
Shareholders' Equity	887.7	927.92	721.5	550.03	171.36	91.98
Net Cash / Debt	689.18	627.18	581.65	543.52	173.68	124.91
Net Cash / Debt Growth	33.71%	7.83%	7.02%	212.94%	39.05%	19.77%
Net Cash Per Share	8.88	9.38	9.61	12.46	5.03	4.82
Working Capital	684.98	617.69	577.6	544.7	167	101.49
Book Value Per Share	11.44	13.87	11.92	12.61	4.96	3.55

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).